BioEurope 2025 is the largest ever held...Korea Pharmaceutical Bio Association to support domestic companies' overseas expansion and strengthening global cooperation

Nov 07, 2025

The largest pharmaceutical bio exhibition in Europe, 'BioEurope 2025' (BIO Europe 2025), was held in Vienna, Austria, from the 3rd to the 5th.

With more than 5,800 people from 55 countries around the world participating in BioEurope, which marks its 31st anniversary this year, Korea has the fourth-largest participant among all participating countries, with more than 460 people from more than 200 companies and institutions.

The Korea Pharmaceutical and Bio Association conducted various activities to strengthen global cooperation and overseas expansion of domestic companies.

During the exhibition, the association's delegation met with major clusters and investment promotion organizations such as Germany, the United States, Japan, and Singapore to introduce the competitiveness and innovation ecosystem of the Korean pharmaceutical bio industry and discuss ways to cooperate to expand into the global market. In particular, they agreed with BioM, a representative bio cluster in Bavaria, Germany, and the need to hold seminars and exchanges between companies to provide market information, laying the foundation for future cooperation expansion.

In addition, the association operated the 「Korea Pavilion」 jointly with the Korea Health Industry Promotion Agency and the National Institute of Toxic Science and introduced the capabilities of the Korean pharmaceutical bio industry and new drug pipelines. Officials from many global pharmaceutical companies and investment institutions conducted active business consultations with Korean companies at the Korean Pavilion and sought various cooperation opportunities.

On the first evening of the exhibition, 'Korea Night' co-hosted by four organizations, including the Korea Exchange, was held with great success. More than 300 domestic and foreign pharmaceutical bio-industry officials attended and discussed wide networking and cooperation in a free atmosphere. At this event, there were also sessions on the Korean KOSDAQ market and bio-company IPO strategy and investment, as well as sessions to introduce AI and data platform cooperation models of domestic companies and medical institutions, drawing high attention from participants.

Even after the exhibition, the association plans to cooperate with KOTRA's European Regional Headquarters and five European Biomedical Collaboration Guides (Frankfurter, Zurich, etc.) to operate online post-consultations and actively support follow-up meetings with overseas buyers.

In addition, the association attended the 「3rd Korea-Austria Economic Cooperation Forum" co-hosted by the Korean Embassy in Austria and the Austrian Ministry of Economy to imprint the innovation capabilities and global competitiveness of the Korean pharmaceutical bio industry on the Austrian government and industry officials. Lee Hyun-woo, managing director of the association, who was the first presenter, emphasized that Korea has the world's third-largest new drug development pipeline based on active R&D investment and open innovation, and that it will continue to strengthen its global competitiveness through partnerships with European pharmaceutical bio companies in the future.

Managing Director Lee Hyun-woo "Once again confirmed that domestic companies participating in BioEurope 2025 are very active in entering overseas markets."In particular, given the high interest and demand for technological exchanges and global investment attraction with foreign companies, the association will continue to strengthen strategic support for biotech companies as well as pharmaceutical companies to create practical cooperation and results in the global market."

This article was translated by Naver AI translator.